163 related articles for article (PubMed ID: 10593449)
1. Differential olanzapine plasma concentrations by sex in a fixed-dose study.
Kelly DL; Conley RR; Tamminga CA
Schizophr Res; 1999 Nov; 40(2):101-4. PubMed ID: 10593449
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring of serum olanzapine during antipsychotic treatment].
Linnet K; Olesen OV
Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
[TBL] [Abstract][Full Text] [Related]
3. [Olanzapine in the first episode of schizophrenia in young adults].
Dabkowska M
Psychiatr Pol; 2002; 36(6 Suppl):235-41. PubMed ID: 12647444
[TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.
Perry PJ; Lund BC; Sanger T; Beasley C
J Clin Psychopharmacol; 2001 Feb; 21(1):14-20. PubMed ID: 11199942
[TBL] [Abstract][Full Text] [Related]
6. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.
Lane HY; Guo SC; Hwang TJ; Chen YS; Cheng JJ; Lee YC; Hong CJ; Hwu HG; Chang WH
J Clin Psychopharmacol; 2002 Oct; 22(5):530-2. PubMed ID: 12352282
[No Abstract] [Full Text] [Related]
7. [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].
Jarema M; Olajossy M; Chrzanowski W; Araszkiewicz A; Landowski J; Rybakowski J; Bilikiewicz A; Bomba J; Debowska G
Psychiatr Pol; 2003; 37(4):641-55. PubMed ID: 14560493
[TBL] [Abstract][Full Text] [Related]
8. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
[TBL] [Abstract][Full Text] [Related]
9. Influence of fluoxetine on olanzapine pharmacokinetics.
Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
[No Abstract] [Full Text] [Related]
11. Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.
Khan M; Farver D
S D J Med; 2000 Feb; 53(2):65-7. PubMed ID: 10731859
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine. Keep an eye on this neuroleptic.
Can Fam Physician; 2000 Feb; 46():322-6, 330-6. PubMed ID: 10690489
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Francobandiera G
Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
[TBL] [Abstract][Full Text] [Related]
14. High-dose olanzapine therapy in schizophrenia.
Alao AO; Armenta WA; Yolles JC
Ann Pharmacother; 1999 Nov; 33(11):1228. PubMed ID: 10573326
[No Abstract] [Full Text] [Related]
15. Intoxication with olanzapine.
Bosch RF; Baumbach A; Bitzer M; Erley CM
Am J Psychiatry; 2000 Feb; 157(2):304-5. PubMed ID: 10671421
[No Abstract] [Full Text] [Related]
16. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.
Bizouard P; Vandel S; Kantelip JP
Therapie; 2001; 56(4):443-5. PubMed ID: 11677871
[No Abstract] [Full Text] [Related]
18. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
Rao ML; Hiemke C; Grasmäder K; Baumann P;
Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
[TBL] [Abstract][Full Text] [Related]
19. D2 receptor occupancy under recommended and high doses of olanzapine.
Harvey EJ; Taylor DM; Flanagan RJ
J Psychopharmacol; 2001 Sep; 15(3):213-4. PubMed ID: 11565632
[No Abstract] [Full Text] [Related]
20. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia.
Fellows L; Ahmad F; Castle DJ; Dusci LJ; Bulsara MK; Ilett KF
Ther Drug Monit; 2003 Dec; 25(6):682-9. PubMed ID: 14639054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
